Skip to main content
padlock icon - secure page this page is secure

Targeting IL-23 and Th17-Cytokines in Inflammatory Bowel Diseases

Buy Article:

$68.00 + tax (Refund Policy)

Over the last 15 years, the use of various biological therapies has largely improved the way we manage patients with Inflammatory Bowel Diseases (IBDs). Blockade of cytokine synthesis and/or activity is at the forefront of this new era with the success of inhibitors of tumor necrosis factor (TNF)-α. These therapies are however not effective in all IBD patients and efficacy may wane. Moreover, patients treated with anti-TNF-α antibodies can develop severe side-effects and new immune-mediated diseases. Therefore, a new challenge is to elucidate new inflammatory networks in the IBD tissue and develop novel anti-cytokine compounds, which may act in patients who are resistant to or cannot receive anti-TNF-α therapies. In this article we review the available data supporting the pathogenic role of IL-23 and Th17-related cytokines in IBD, and discuss whether and how compounds that control the activity of these cytokines may enter into the therapeutic armamentarium of IBD.





No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: ABT-874; Bacteroides fragilis; CD4 cells; Crohn's disease; IBD; IL-12; IL-17A; IL-21; IL-23; Inflammatory Bowel Diseases; Neutralization; SCID mice; T cells; TNBS-colitis; Th17; Th17-Cytokines; anti-TNF- antibodies; anti-cytokine therapy; chemokines; granulocytes; homeostasis; interferon; interleukin; monoclonal antibody; polymorphisms; retinoic acid-related orphan receptor; trinitrobenzenesulfonic acid; tumor necrosis factor; tumours; ulcerative colitis

Document Type: Research Article

Publication date: November 1, 2010

More about this publication?
  • Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.

    Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more